ProQR Therapeutics BV (PRQR) — Cash Flow-to-Debt Ratio
ProQR Therapeutics BV (PRQR) has a Cash Flow-to-Debt Ratio of -0.18x as of September 2025, meaning its operating cash flow of $-12.23 Million could theoretically repay 0% of its total liabilities ($67.28 Million) in one year. See PRQR FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
ProQR Therapeutics BV Cash Flow-to-Debt Ratio (2013–2024)
Historical debt coverage capacity for ProQR Therapeutics BV across 12 annual periods. Also explore net asset momentum of ProQR Therapeutics BV to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for ProQR Therapeutics BV (2013–2024)
Year-by-year debt coverage analysis for ProQR Therapeutics BV. For market capitalisation and broader financial context, see market cap of ProQR Therapeutics BV.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.46x | $-36.39 Million | $79.40 Million | ▼ -326.7% |
| 2023 | 0.20x | $21.55 Million | $106.59 Million | ▲ +130.9% |
| 2022 | -0.65x | $-68.51 Million | $104.64 Million | ▼ -142.5% |
| 2021 | -0.27x | $-26.01 Million | $96.35 Million | ▲ +70.4% |
| 2020 | -0.91x | $-47.06 Million | $51.61 Million | ▲ +44.8% |
| 2019 | -1.65x | $-43.97 Million | $26.61 Million | ▲ +5.5% |
| 2018 | -1.75x | $-30.68 Million | $17.55 Million | ▲ +31.1% |
| 2017 | -2.54x | $-34.95 Million | $13.78 Million | ▲ +8.0% |
| 2016 | -2.76x | $-34.22 Million | $12.41 Million | ▼ -17.4% |
| 2015 | -2.35x | $-24.23 Million | $10.31 Million | ▲ +5.0% |
| 2014 | -2.47x | $-14.46 Million | $5.84 Million | ▼ -387.3% |
| 2013 | -0.51x | $-2.33 Million | $4.59 Million | — |